Peptides and Peptidomimetics as antimicrobial therapeutic agents
Context
Antibiotic resistance is currently a major public health challenge and one of the priorities of the World Health Organization. It is responsible for 750,000 deaths per year and is expected to increase to 10 million by 2050. This dramatic situation is leading scientists to search for new molecules with different structures and mode of action to overcome resistance. Lately, our laboratory has been successfully exploring different strategies to combat this resistance by identifying and characterizing new antimicrobials [1-4]. Among them, our group has demonstrated the potent activity of temporins (amphibian AMPs) and lynronnes (ruminal AMPs obtained by metagenomics approach) against various bacteria infecting humans (H. pylori, S. aureus, P. aeruginosa, …) and their safety toward human cells and tissues [5-9].
